Fully automated calcium scoring predicts all-cause mortality at 12 years in the MILD lung cancer screening trial
PLOS ONE · 16.05.2023 · 18 (5) · e0285593
DOI: 10.1371/journal.pone.0285593 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 16.05.2023. Verfasst von Federica Sabia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Hauptthemen laut MEDLINE: Coronary Artery Disease, Lung Neoplasms, Vascular Calcification. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Ministero della Salute, Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
Coronary artery calcium (CAC) is a known risk factor for cardiovascular (CV) events and mortality but is not yet routinely evaluated in low-dose computed tomography (LDCT)-based lung cancer screening (LCS). The present analysis explored the capacity of a fully automated CAC scoring to predict 12-year mortality in the Multicentric Italian Lung Detection (MILD) LCS trial. The study included 2239 volunteers of the MILD trial who underwent a baseline LDCT from September 2005 to January 2011, with a median follow-up of 190 months. The CAC score was measured by a commercially available fully automated artificial intelligence (AI) software and stratified into five strata: 0, 1–10, 11–100, 101–400, and > 400. Twelve-year all-cause mortality was 8.5% (191/2239) overall, 3.2% with CAC = 0, 4.9% with CAC = 1–10, 8.0% with CAC = 11–100, 11.5% with CAC = 101–400, and 17% with CAC > 400. In Cox proportional hazards regression analysis, CAC > 400 was associated with a higher 12-year all-cause mortality both in a univariate model (hazard ratio, HR, 5.75 [95% confidence interval, CI, 2.08–15.92] compared to CAC = 0) and after adjustment for baseline confounders (HR, 3.80 [95%CI, 1.35–10.74] compared to CAC = 0). All-cause mortality significantly increased with increasing CAC (7% in CAC ≤ 400 vs. 17% in CAC > 400, Log-Rank p-value 400 (Grey’s test p < 0.001). In Fine and Gray’s competing risk model, CAC > 400 predicted 12-year non-cancer mortality in a univariate model (sub-distribution hazard ratio, SHR, 10.62 [95% confidence interval, CI, 1.43–78.98] compared to CAC = 0), but the association was no longer significant after adjustment for baseline confounders. In conclusion, fully automated CAC scoring was effective in predicting all-cause mortality at 12 years in a LCS setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Section of Radiology, Department of Medicine and Surgery (DiMeC), University Hospital of Parma, Parma, Italy.
- Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
ORCID-Profile: Maurizio Balbi, Ugo Pastorino
Förderung
- NCI NIH HHS
- Ministero della Salute
- Associazione Italiana per la Ricerca sul Cancro
- Fondazione Cariplo
- National Cancer Institute
Zitieren
APA
Sabia, F., Balbi, M., Ledda, R. E., Milanese, G., Ruggirello, M., Valsecchi, C., Marchianò, A., Sverzellati, N., & Pastorino, U. (2023). Fully automated calcium scoring predicts all-cause mortality at 12 years in the MILD lung cancer screening trial. PLOS ONE, 18(5), e0285593. https://doi.org/10.1371/journal.pone.0285593
Vancouver
Sabia F, Balbi M, Ledda RE, Milanese G, Ruggirello M, Valsecchi C, et al. Fully automated calcium scoring predicts all-cause mortality at 12 years in the MILD lung cancer screening trial. PLOS ONE. 2023;18(5):e0285593. doi:10.1371/journal.pone.0285593
BibTeX
@article{Sabia2023,
author = {Sabia, Federica and Balbi, Maurizio and Ledda, Roberta E and Milanese, Gianluca and Ruggirello, Margherita and Valsecchi, Camilla and Marchianò, Alfonso and Sverzellati, Nicola and Pastorino, Ugo},
title = {Fully automated calcium scoring predicts all-cause mortality at 12 years in the MILD lung cancer screening trial},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {5},
pages = {e0285593},
doi = {10.1371/journal.pone.0285593}
}
EUVIMED